Prevalence of pediatric alopecia areata among 572,617 dermatology patients To the Editor: The authors initiated this retrospective analysis to evaluate the prevalence, age, and sex of pediatric patients with alopecia areata (AA) and the impact that pediatric AA has on a typical dermatology practice. Billing data from Leavitt Medical Associates of Florida, doing business under the name Advanced Dermatology and Cosmetic Surgery, was collected from offices throughout Florida and Ohio, and 572,617 dermatology patients were identified. The study population included 71,951 pediatric patients (1-17 years of age): 33,800 boys and 37,791 girls.
Of all 572,617 dermatology patients, 3633 had AA (0.63%). Of 71,951 pediatric patients, 656 had AA. Girls (n ¼ 365) outnumbered boys (n ¼ 291) (P ¼ .004) with a ratio of 1.25:1. Overall, pediatric patients with AA were 18.1% (656/3633) of all patients with AA and 11.9% (656/5520) of all patients with any hair abnormality. Pediatric AA patients represented 0.1% (656/572,617) of all patients and 0.9% (656/71,591) of pediatric patients. The prevalence distribution of both sexes resembled a bell-shaped curve, with boys peaking at 12 years of age and girls peaking at 9 years of age (Fig 1) .
To compare the prevalence of AA among different age groups, the patients were divided into 3 broad groups: toddlers (1-5 years of age), children (6-11 years of age), and adolescents (12-17 years of age). Table I shows the prevalence of AA in these age groups.
In 2004, Stern estimated that 9598 total US officebased dermatologists see 47,990,000 dermatology patients per year, with the average dermatologist Age and sex distribution of pediatric alopecia areata patients. Data is presented as the proportion of pediatric patients with alopecia areata of one sex (or both sexes for total) per 1000 pediatric patients of that same sex (or both sexes for total). AA, Alopecia areata. seeing ;5000 patients per year. 1 Given our prevalence of a diagnosis of AA in 0.63% (3633/572,617) of dermatology patients of all ages, we estimate that 302,337 patients with AA visit US dermatology practices each year. A 1992 study reported a similar nationwide prevalence of 306,000 AA patients. 2 Our study found that pediatric AA patients represented 18.1% of AA patients of all ages. Thus, we estimate that ;54,000 pediatric AA patients visit dermatology offices per year. McMichael et al reported that 16% of total visits for AA involved patients 0-19 years of age, 3 and Safavi et al found that 27.7% of 292 AA patients were 0-19 years of age. 4 The rate of 5000 dermatology patients per year per dermatologist noted above can be viewed as 21 patients per day (assuming a 5-day work week 52 weeks/year) or 1000 patients in ;2.4 months. 3 On the basis of our data, pediatric patients represent 126 of these 1000 patients; 10 of 126 will have a hair condition, and 1 of 126 will have AA. Thus, on average, 1 pediatric patient with AA will appear for treatment at a private dermatology office in the United States every 2.4 months; this single AA patient is 1.25 times more likely to be a girl than a boy. Reprints not available from the authors.
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Lack of an association between alopecia areata and visceral or hematopoietic cancers
To the Editor: Alopecia areata (AA) is a polygenic, patchy nonscarring hair loss that presents on the scalp and body that drastically affects patients' quality of life. 1 The pathogenesis of AA remains elusive, though T-lymphocyteemediated inflammation and various environmental stressors play a role. The association between AA and various autoimmune diseases has been explored in several studies. 1 Recently, studies found lower rates of nonmelanoma skin cancers and a trend toward decreased melanoma among AA patients.
2,3 To our knowledge, no studies have assessed the association between AA and systemic malignancy. The current popularity of Janus kinase inhibitors for AA highlights the need to further investigate this association because they theoretically increase the risk for malignancy. 4 This research letter provides a review of the Cleveland Clinic Alopecia Registry specifically looking at all cancers present in patients with AA to add to the growing literature base characterizing this multifactorial disease.
A retrospective chart review was performed with the Cleveland Clinic Alopecia Registry on AA patients with varying degrees of severity who sought treatment during 2005-2016 (n ¼ 636). A control group of age-matched patients given diagnoses of seborrheic dermatitis (SD) without hair loss was randomly selected (n ¼ 215). Hair loss specialists assessed the control group for the absence of hair loss to ensure validity. Data were collected on sex, age, and presence of visceral cancers. The inclusion criterion was diagnosis of AA or SD by a Cleveland Clinic dermatologist. The presence of systemic cancers in the AA group and the control group was determined by manual chart review. Demographic and clinical variables were compared using t-test, 2 test, and Fisher's exact test. Significance was considered at an ¼ 0.05.
